Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Oct 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how autoimmune encephalitis affects the way the brain uses glucose, which is a type of sugar that provides energy to our cells. Researchers are looking at a group of 56 patients who have been diagnosed with autoimmune encephalitis. The goal is to see how this condition impacts brain metabolism during the early stages of illness, either before treatment begins or within 10 days of starting treatment.

To be eligible for this study, participants must be at least 18 years old and have recently been diagnosed with autoimmune encephalitis, meeting specific medical criteria. They should not have a history of certain brain conditions or have been on certain treatments for more than 10 days. If someone joins the study, they will undergo a special imaging test called an FDG PET scan, which helps to visualize how their brain is functioning. It’s important for participants to be able to remain still during the scan, and they will need to give their consent or have a family member or legal representative do so. This trial is currently recruiting participants, and it aims to improve our understanding of autoimmune encephalitis to help develop better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old
• * Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following criteria :
• • 1. " Definite limbic autoimmune encephalitis " according to 2016 Graus et al. criteria
• • 2. " Possible autoimmune encephalitis " according to 2016 Graus et al. criteria AND typical autoantibody detected in serum or CSF
• • 3. " Probable or certain paraneoplastic neurological syndrome " according to Graus et al. 2021 criteria (excluding peripheral neurological syndromes)
• • Less than 6 months since first neurological symptoms imputable to autoimmune encephalitis
• • Affiliated or entitled to a social security system (except AME)
• • Obtaining free, written and informed consent (patient or legal representative or the close relative)
• • Exclusion criteria
• • History of brain tumor, head trauma, infarction or cerebral hematoma likely to result in altered cerebral carbohydrate metabolism on PET
• • Patients who hae been on immunotherapy (corticosteroid bolus, IVIg, plasma exchange, endoxan, rituximab or other immunotherapy) fr more than 10 days
• • Pregnant or breast-feeding woman
• • Ventilated intubated patient
• • Absolute contraindication to MRI (Pacemaker, cochlear implant, etc.)
• • Presence of cognitive disorders incompatible with goog cooperation with the PET scan
• • Algic or agitated patient unable to remain immobile in supine position for 30 minutes
• • Deprived of liberty or under a protective measure (guardianship or curatorship)
• • Patient taking part in other interventional research involving radiopharmaceutical injections